Aurobindo Pharma receives USFDA approval for Azithromycin Tablets

11 Jul 2018 Evaluate

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture Azithromycin tablets 250 mg and 500 mg. Azithromycin tablets are an AB-rated generic equivalent of Pfizer Inc’s Zithromax tablets. The product will be launched in July 2018.

Azithromycin tablets are indicated for the treatment of patients with mild to moderate infections. The approved product has an estimated market size of $132 million for the twelve months ending May 2018 according to IQVIA.

This is the 146th ANDA (including 19 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India used for manufacturing oral products. Aurobindo now has a total of 377 ANDA approvals (344 Final approvals including 17 from Aurolife Pharma LLC and 33 tentative approvals) from USFDA.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1225.80 0.50 (0.04%)
23-May-2024 15:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1494.95
Dr. Reddys Lab 5882.45
Cipla 1487.45
Zydus Lifesciences 1087.65
Lupin 1631.60
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.